Gabriel Ghiaur

Gabriel Ghiaur

Oncology | Hematology
401 North Broadway Street, Weinberg BLDG
Weinberg BLDG
Baltimore, MD 21287

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 103 publications

Chemotherapy regimens with second generation tyrosine kinase inhibitors for BCR-ABL B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation.

Chemotherapy regimens with second generation tyrosine kinase inhibitors for BCR-ABL B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation.

Journal: Leukemia & lymphoma
Published: February 15, 2026

Evolution to complex karyotype disease in mono-allelic TP53-mutated myelodysplastic syndrome/acute myeloid leukemia: a cohort study.

Evolution to complex karyotype disease in mono-allelic TP53-mutated myelodysplastic syndrome/acute myeloid leukemia: a cohort study.

Journal: Haematologica
Published: February 15, 2026

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML including TP53-mutated disease.

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML including TP53-mutated disease.

Journal: Blood advances
Published: December 11, 2025

A PBD dimer-containing antibody-drug conjugate targeting CCRL2 for high-risk MDS/AML including TP53-mutated disease.

A PBD dimer-containing antibody-drug conjugate targeting CCRL2 for high-risk MDS/AML including TP53-mutated disease.

Journal: Blood advances
Published: December 11, 2025

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML.

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML.

Journal: Research square
Published: November 24, 2025

FLT3: A 35-Year Voyage from Discovery to the Next Generation of Targeted Therapy in AML.

FLT3: A 35-Year Voyage from Discovery to the Next Generation of Targeted Therapy in AML.

Journal: Cancers
Published: September 25, 2025

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML.

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML.

Journal: bioRxiv : the preprint server for biology
Published: September 02, 2025

Advances in measurable residual disease assessment for acute myeloid leukemia: from cytogenetics and molecular biology to assessment of the methylation pattern and surface-enhanced Raman scattering as emerging technologies.

Advances in measurable residual disease assessment for acute myeloid leukemia: from cytogenetics and molecular biology to assessment of the methylation pattern and surface-enhanced Raman scattering as emerging technologies.

Journal: Biomarker research
Published: July 16, 2025

Efficacy and safety of blinatumomab for CD19 + acute leukemias in patients historically excluded from clinical trials due to comorbidities.

Efficacy and safety of blinatumomab for CD19 + acute leukemias in patients historically excluded from clinical trials due to comorbidities.

Journal: Leukemia research
Published: June 25, 2025

Serine auxotrophy is a targetable vulnerability driven by PSAT1 suppression in AML.

Serine auxotrophy is a targetable vulnerability driven by PSAT1 suppression in AML.

Journal: bioRxiv : the preprint server for biology
Published: June 04, 2025

Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML.

Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML.

Journal: Blood neoplasia
Published: April 10, 2025

Humanized mouse models in MDS.

Humanized mouse models in MDS.

Journal: Cell death & disease
Published: March 18, 2025
Showing 1-12 of 103

Last Updated: 09/26/2026